103 related articles for article (PubMed ID: 23939261)
1. Design and evaluation of levodopa methyl ester intranasal delivery systems.
Chun IK; Lee YH; Lee KE; Gwak HS
J Parkinsons Dis; 2011; 1(1):101-7. PubMed ID: 23939261
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic evaluation of formulated levodopa methyl ester nasal delivery systems.
Lee YH; Kim KH; Yoon IK; Lee KE; Chun IK; Rhie JY; Gwak HS
Eur J Drug Metab Pharmacokinet; 2014 Dec; 39(4):237-42. PubMed ID: 24363125
[TBL] [Abstract][Full Text] [Related]
3. Potential transbuccal delivery of l-DOPA methylester prodrug: stability in the environment of the oral cavity and ability to cross the mucosal tissue.
Scaturro AL; De Caro V; Campisi G; Giannola LI
Drug Deliv; 2016 Sep; 23(7):2355-2362. PubMed ID: 25533875
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of the systemic and CNS specific delivery of L-dopa by the nasal administration of its water soluble prodrugs.
Kao HD; Traboulsi A; Itoh S; Dittert L; Hussain A
Pharm Res; 2000 Aug; 17(8):978-84. PubMed ID: 11028945
[TBL] [Abstract][Full Text] [Related]
5. Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats.
Yang X; Zheng R; Cai Y; Liao M; Yuan W; Liu Z
Int J Nanomedicine; 2012; 7():2077-86. PubMed ID: 22619544
[TBL] [Abstract][Full Text] [Related]
6. Determination of levodopa methyl ester and its metabolites in rat serum by CZE with amperometric detection.
Wang J; Zhou Y; Wang AF; Zhang SH; Ning L; He PG; Fang YZ
Anal Bioanal Chem; 2005 May; 382(1):198-203. PubMed ID: 15900472
[TBL] [Abstract][Full Text] [Related]
7. The clinical efficacy of a single afternoon dose of levodopa methyl ester: a double-blind cross-over study versus placebo.
Stocchi F; Barbato L; Bramante L; Bonamartini A; Ruggieri S
Funct Neurol; 1994; 9(5):259-64. PubMed ID: 7750809
[TBL] [Abstract][Full Text] [Related]
8. Sustained-release formulation of levodopa methyl ester/benserazide for prolonged suppressing dyskinesia expression in 6-OHDA-leisoned rats.
Ren T; Yang X; Wu N; Cai Y; Liu Z; Yuan W
Neurosci Lett; 2011 Sep; 502(2):117-22. PubMed ID: 21835223
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic evaluation and modeling of formulated levodopa intranasal delivery systems.
Kim TK; Kang W; Chun IK; Oh SY; Lee YH; Gwak HS
Eur J Pharm Sci; 2009 Dec; 38(5):525-32. PubMed ID: 19804823
[TBL] [Abstract][Full Text] [Related]
10. Formulation and characterization of intranasal mucoadhesive nanoparticulates and thermo-reversible gel of levodopa for brain delivery.
Sharma S; Lohan S; Murthy RS
Drug Dev Ind Pharm; 2014 Jul; 40(7):869-78. PubMed ID: 23600649
[TBL] [Abstract][Full Text] [Related]
11. Formulation and in vitro/in vivo evaluation of levodopa transdermal delivery systems.
Lee KE; Choi YJ; Oh BR; Chun IK; Gwak HS
Int J Pharm; 2013 Nov; 456(2):432-6. PubMed ID: 24008082
[TBL] [Abstract][Full Text] [Related]
12. Levodopa delivery systems: advancements in delivery of the gold standard.
Ngwuluka N; Pillay V; Du Toit LC; Ndesendo V; Choonara Y; Modi G; Naidoo D
Expert Opin Drug Deliv; 2010 Feb; 7(2):203-24. PubMed ID: 20095943
[TBL] [Abstract][Full Text] [Related]
13. Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure.
Smith LA; Jackson MJ; Hansard MJ; Maratos E; Jenner P
Mov Disord; 2003 May; 18(5):487-95. PubMed ID: 12722161
[TBL] [Abstract][Full Text] [Related]
14. L-dopa methyl ester attenuates amblyopia-induced neuronal injury in visual cortex of amblyopic cat.
Li R; Liang T; Chen Z; Zhang S; Lin X; Huang R
Gene; 2013 Sep; 527(1):115-22. PubMed ID: 23774688
[TBL] [Abstract][Full Text] [Related]
15. Determination, purity assessment and chiral separation of levodopa methyl ester in bulk and formulation pharmaceuticals.
Wang J; Fang Y
Biomed Chromatogr; 2006 Sep; 20(9):904-10. PubMed ID: 16389643
[TBL] [Abstract][Full Text] [Related]
16. Preparation and in vitro characterization of gelatin microspheres containing Levodopa for nasal administration.
Brime B; Ballesteros MP; Frutos P
J Microencapsul; 2000; 17(6):777-84. PubMed ID: 11063424
[TBL] [Abstract][Full Text] [Related]
17. Formulation of levodopa containing dry powder for nasal delivery applying the quality-by-design approach.
Bartos C; Pallagi E; Szabó-Révész P; Ambrus R; Katona G; Kiss T; Rahimi M; Csóka I
Eur J Pharm Sci; 2018 Oct; 123():475-483. PubMed ID: 30076956
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of rat striatal L-dopa and DA concentration after intraperitoneal administration of L-dopa prodrugs in liposomal formulations.
Di Stefano A; Carafa M; Sozio P; Pinnen F; Braghiroli D; Orlando G; Cannazza G; Ricciutelli M; Marianecci C; Santucci E
J Control Release; 2004 Sep; 99(2):293-300. PubMed ID: 15380638
[TBL] [Abstract][Full Text] [Related]
19. Influence of layer position on in vitro and in vivo release of levodopa methyl ester and carbidopa from three-layer matrix tablets.
Bettini R; Acerbi D; Caponetti G; Musa R; Magi N; Colombo P; Cocconi D; Santi P; Catellani PL; Ventura P
Eur J Pharm Biopharm; 2002 Mar; 53(2):227-32. PubMed ID: 11880007
[TBL] [Abstract][Full Text] [Related]
20. L-DOPA cyclohexyl ester is a novel stable and potent competitive antagonist against L-DOPA, as compared to L-DOPA methyl ester.
Misu Y; Goshima Y; Miyamae T; Furukawa N; Sugiyama Y; Okumura Y; Shimizu M; Ohshima E; Suzuki F
Jpn J Pharmacol; 1997 Nov; 75(3):307-9. PubMed ID: 9434265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
